Ianalumab is a monoclonal antibody commercialized by Novartis, with a leading Phase III program in Acquired (Autoimmune) Hemolytic Anemia;Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura). According to Globaldata, it is involved in 22 clinical trials, of which 3 were completed, 14 are ongoing, 1 is planned, and 4 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Ianalumab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Ianalumab is expected to reach an annual total of $24 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Ianalumab is under development for the treatment of autoimmune hepatitis, chronic lymphocytic leukemia, primary Sjogren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, B-Cell Non-Hodgkin Lymphomas including diffuse large B-cell lymphoma, follicular lymphoma (FL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), autoimmune hemolytic anemia, primary immune thrombocytopenia and lupus nephritis. The therapeutic candidate is administered through subcutaneous and intravenous routes. It is a monoclonal antibody that acts by targeting BAFF receptor (BAFF-R). The therapeutic candidate is based on HuCAL (human combinatorial antibody library) technology. It is a new molecular entity (NME).
The drug candidate was also under development for the treatment of relapsed or refractory chronic lymphocytic leukemia, pemphigus vulgaris, idiopathic pulmonary fibrosis and relapsing-remitting multiple sclerosis (RRMS).
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
The company reported revenues of (US Dollars) US$51,742 million for the fiscal year ended December 2022 (FY2022), a decrease of 2.1% over FY2021. In FY2022, the company’s operating margin was 17.8%, compared to an operating margin of 22.1% in FY2021. In FY2022, the company recorded a net margin of 13.4%, compared to a net margin of 45.4% in FY2021. The company reported revenues of US$13,208 million for the first quarter ended March 2023, an increase of 1.6% over the previous quarter.
For a complete picture of Ianalumab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.